Valuation: Evotec SE

Market Cap 562M 623M 519M 469M 888M 58.45B 909M 6.22B 2.48B 31.3B 2.34B 2.29B 99.62B P/E 2026 *
-2.15x
P/E 2027 * -5.95x
Enterprise Value 729M 809M 674M 609M 1.15B 75.87B 1.18B 8.07B 3.22B 40.63B 3.04B 2.97B 129B EV / Sales 2026 *
1.22x
EV / Sales 2027 * 1.12x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day+1.35%
1 week+9.49%
Current month+12.14%
1 month+14.16%
3 months-14.73%
6 months-39.23%
Current year-42.02%
1 week 3.03
Extreme 3.026
3.32
1 month 2.41
Extreme 2.406
3.32
Current year 2.41
Extreme 2.406
6.73
1 year 2.41
Extreme 2.406
6.73
3 years 2.41
Extreme 2.406
21.69
5 years 2.41
Extreme 2.406
44.94
10 years 2.41
Extreme 2.406
45.83
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Date Insider Type Main position Quantity % Market Cap. Importance
20/5/26 Exercice

Chief Technology Officer

12,462 0.0070%
4/5/26 Buy 15,510 0.0087%
4/5/26 Buy

Head of Human Resources

15,228 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+1.35%+9.49%-38.11%-81.89% 618M
-1.06%-0.07%+60.76%+68.61% 68.32B
+1.30%+7.41%+14.79%+92.69% 60.26B
+0.39%+0.30%+20.04%+98.33% 55.86B
-0.95%+11.17%+22.21%+110.93% 48.43B
-0.23%+4.07%+25.63%+40.08% 45.34B
-6.40%-9.51%+181.99%+816.79% 41.76B
+1.97%+3.50%+25.78%+50.98% 34.5B
-0.56%-0.48%+85.57%+65.40% 33.8B
+1.05%+9.77%-37.66%+408.42% 26.21B
Average -0.31%+2.26%+36.10%+167.04% 42B
Weighted average by Cap. -0.53%+1.45%+45.22%+172.70%

Financials

2026 *2027 *
Net sales 600M 665M 554M 501M 948M 62.4B 971M 6.64B 2.65B 33.42B 2.5B 2.44B 106B 709M 786M 655M 592M 1.12B 73.74B 1.15B 7.85B 3.13B 39.49B 2.95B 2.89B 126B
Net income -280M -310M -258M -234M -442M -29.11B -453M -3.1B -1.23B -15.59B -1.16B -1.14B -49.62B -62.33M -69.16M -57.59M -52.06M -98.49M -6.49B -101M -690M -275M -3.47B -260M -254M -11.05B
Net Debt 167M 186M 155M 140M 264M 17.41B 271M 1.85B 739M 9.33B 697M 682M 29.68B 234M 259M 216M 195M 369M 24.3B 378M 2.59B 1.03B 13.01B 972M 952M 41.41B
Projected Income Statement - Annual - Evotec SE
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,379
Date Price Change Volume
11/11/26 EUR 3.160 +1.35% 958,567
10/11/26 EUR 3.118 -0.76% 930,957
09/11/26 EUR 3.142 -0.70% 1,288,676
06/11/26 EUR 3.164 +2.33% 1,639,531
05/11/26 EUR 3.092 +7.14% 2,443,451
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Evotec SE
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.160EUR
Average target price
3.750EUR
Spread / Average Target
+18.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evotec SE